Nyxoah (NASDAQ:NYXH – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.
Insider and Institutional Ownership
16.4% of Nanovibronix shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 12.2% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Nyxoah and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -443.16% | -178.90% | -81.83% |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $11.33 million | 4.65 | -$101.92 million | ($2.52) | -0.54 |
| Nanovibronix | $1.93 million | 0.17 | -$18.18 million | ($117.28) | -0.00 |
Nanovibronix has lower revenue, but higher earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Nyxoah has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Nyxoah and Nanovibronix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 1 | 1 | 2 | 0 | 2.25 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Nyxoah presently has a consensus price target of $4.26, suggesting a potential upside of 213.38%. Given Nyxoah’s stronger consensus rating and higher possible upside, research analysts plainly believe Nyxoah is more favorable than Nanovibronix.
Summary
Nyxoah beats Nanovibronix on 9 of the 14 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
